
11 - 50 employees
🏥 Healthcare
💼 Consulting
🍽️ Food & Beverage
Healthcare • Consulting • Food & Beverage
Pulmovant is a company committed to transforming the lives of patients with pulmonary diseases by developing innovative therapies. Their lead product, mosliciguat, aims to provide a once-daily, inhaled treatment for pulmonary hypertension, distinguished by its novel sGC activation mechanism. With a singular focus on addressing the unique needs of patients suffering from pulmonary conditions, Pulmovant is engaged in extensive clinical trials to advance its pioneering treatment options.
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 6 days ago
Senior program manager advancing Pulmovant’s PH-ILD drug development studies. Coordinating cross-functional teams, timelines, risks, and deliverables for mosliciguat supporting studies.
🕒 September 28
Statistical programming manager advancing Pulmovant’s pulmonary disease clinical trials. Delivering SAS/R datasets, TLFs, and regulatory submissions.
🕒 September 25
Senior Clinical Supply Manager advancing Pulmovant’s pulmonary hypertension drug trials. Managing global clinical packaging, inventory, logistics, vendors, and distribution.
🕒 September 25
Senior Regulatory Affairs leader guiding Pulmovant’s mosliciguat, an inhaled pulmonary hypertension therapy, through global clinical development and approval. Shaping FDA and international submission strategy.
🕒 September 24
Associate Director leading drug substance process development, scale-up, and CDMO tech transfer. Advancing Pulmovant’s inhaled pulmonary hypertension therapy toward Phase 3 and commercial manufacturing.
🕒 September 23
Director of Biostatistics leading statistical strategy for Pulmovant’s Phase 3 PH-ILD trial. Driving regulatory-ready analyses for its inhaled mosliciguat treatment.
🕒 September 23
Senior Pharmacovigilance Manager overseeing drug safety for Pulmovant’s respiratory biotechnology pipeline. Managing clinical-trial surveillance, regulatory reporting, signal detection, and PV vendors.
🕒 September 22
Clinical Development Lead guiding mosliciguat’s Phase 3 pulmonary hypertension trial at Pulmovant. Providing medical oversight, protocol leadership, and regulatory collaboration for pulmonary disease treatments.
🕒 September 10
Clinical Supply Director managing packaging, labeling, inventory, and distribution for Pulmovant’s global pulmonary-disease trials. Leading vendors, clinical supply managers, and cGxP-compliant operations.
🕒 August 25
Regulatory Affairs leader advancing Pulmovant’s inhaled pulmonary disease therapies through global clinical and registration approvals. Guiding FDA and international submissions, health-authority interactions, and cross-functional regulatory strategy.